Maravai Competitors

MRVI Stock  USD 5.93  0.50  9.21%   
Maravai Lifesciences competes with Roivant Sciences, Krystal Biotech, Akero Therapeutics, Apellis Pharmaceuticals, and Halozyme Therapeutics; as well as few others. The company conducts business under Life Sciences Tools & Services sector and is part of Health Care industry. Analyzing Maravai Lifesciences competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Maravai Lifesciences to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Maravai Lifesciences Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Maravai Lifesciences competition on your existing holdings.
  
The Maravai Lifesciences' current Return On Tangible Assets is estimated to increase to -0.12. The Maravai Lifesciences' current Return On Capital Employed is estimated to increase to -0.02. As of now, Maravai Lifesciences' Intangibles To Total Assets are decreasing as compared to previous years. The Maravai Lifesciences' current Debt To Assets is estimated to increase to 0.46, while Total Assets are projected to decrease to under 1.5 B.
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Maravai Lifesciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.295.8312.16
Details
Intrinsic
Valuation
LowRealHigh
1.227.5513.88
Details
Naive
Forecast
LowNextHigh
0.126.2312.56
Details
15 Analysts
Consensus
LowTargetHigh
11.8313.0014.43
Details

Maravai Lifesciences Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Maravai Lifesciences and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Maravai and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Maravai Lifesciences does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
AKRORXDX
KRYSROIV
APLSKRYS
APLSROIV
RAREHALO
AGIOAKRO
  
High negative correlations   
RAREAGIO
RARERXDX
HALORXDX
RAREAKRO
AGIOHALO
APLSAKRO

Risk-Adjusted Indicators

There is a big difference between Maravai Stock performing well and Maravai Lifesciences Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Maravai Lifesciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
ROIV  1.28 (0.14) 0.00 (0.06) 0.00 
 2.66 
 8.89 
KRYS  1.82 (0.19)(0.05) 0.00  2.18 
 4.45 
 12.22 
RXDX  2.40  1.08  0.50 (2.43) 0.76 
 2.76 
 70.71 
AKRO  2.48  0.05  0.05  0.14  2.75 
 5.23 
 13.37 
APLS  2.46 (0.27) 0.00 (0.19) 0.00 
 4.57 
 15.91 
HALO  2.26 (0.38) 0.00 (0.16) 0.00 
 3.90 
 28.41 
AGIO  2.60 (0.16) 0.01  0.05  4.53 
 5.24 
 31.56 
INSM  1.73 (0.15)(0.03) 0.02  2.25 
 3.99 
 14.32 
CERE  0.77  0.07 (0.04) 1.02  0.94 
 1.91 
 6.40 
RARE  1.51 (0.25) 0.00 (0.32) 0.00 
 2.66 
 8.73 

Cross Equities Net Income Analysis

Compare Maravai Lifesciences and related stocks such as Roivant Sciences, Krystal Biotech, and Prometheus Biosciences Net Income Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
ROIV(1 B)(1 B)(1 B)(1 B)(1 B)(1 B)(1 B)(1 B)(1 B)1.2 B(809.2 M)(845.3 M)(1 B)4.3 B4.6 B
KRYS(1.1 M)(1.1 M)(1.1 M)(1.1 M)(1.1 M)(1.1 M)(1.1 M)(7.9 M)(10.9 M)(19.1 M)(32.2 M)(69.6 M)(140 M)10.9 M11.5 M
AKRO(4.6 M)(4.6 M)(4.6 M)(4.6 M)(4.6 M)(4.6 M)(4.6 M)(4.6 M)(81.7 M)(43.8 M)(79.2 M)(100.7 M)(108.9 M)(151.8 M)(144.2 M)
APLS(4 M)(4 M)(4 M)(4 M)(10.8 M)(46.5 M)(27.1 M)(51 M)(127.5 M)(309.8 M)(344.9 M)(746.4 M)(652.2 M)(528.6 M)(502.2 M)
HALO(39.7 K)(19.8 M)(53.6 M)(83.5 M)(68.4 M)(32.2 M)(103 M)63 M(80.3 M)(72.2 M)129.1 M402.7 M202.1 M281.6 M295.7 M
AGIO(23.7 M)(23.7 M)(20.1 M)(39.4 M)(53.5 M)(117.7 M)(198.5 M)(314.7 M)(346 M)(396.6 M)(335.2 M)1.6 B(74.6 M)(352.1 M)(334.5 M)
INSM(7.8 M)(59.7 M)(41.4 M)(56.1 M)(79.2 M)(118.2 M)(176.3 M)(192.6 M)(324.3 M)(254.3 M)(294.1 M)(434.7 M)(481.5 M)(749.6 M)(712.1 M)
RARE(6.8 M)(6.8 M)(16.3 M)(35.1 M)(59.8 M)(145.6 M)(245.9 M)(302.1 M)(197.6 M)(402.7 M)(186.6 M)(454 M)(707.4 M)(606.6 M)(576.3 M)
ALEC(15.1 M)(15.1 M)(15.1 M)(15.1 M)(15.1 M)(15.1 M)(15.1 M)(32.5 M)(52.2 M)(99.8 M)(183 M)(28 M)(133.3 M)(130.4 M)(136.9 M)
LEGN9.4 M9.4 M9.4 M9.4 M9.4 M9.4 M9.4 M9.4 M(2.8 M)(133 M)(303.5 M)(386.2 M)(446.3 M)(518.3 M)(492.3 M)
ASND1.2 M1.2 M1.2 M4.1 M(9.7 M)(32.9 M)(68.5 M)(123.9 M)(130.1 M)(218 M)(419 M)(383.6 M)(583.2 M)(481.4 M)(457.4 M)
CYTK(13.1 M)(47.9 M)(39 M)(33.7 M)(14.6 M)(37.5 M)16.5 M(127.8 M)(106.3 M)(149.1 M)(164.1 M)(242.4 M)(402.6 M)(526.2 M)(499.9 M)
EWTX(9.5 M)(9.5 M)(9.5 M)(9.5 M)(9.5 M)(9.5 M)(9.5 M)(9.5 M)(9.5 M)(9.5 M)(17.1 M)(42.1 M)(15.4 M)(100.2 M)(95.2 M)
FOLD(6.8 M)(44.4 M)(48.8 M)(59.6 M)(68.9 M)(132.1 M)(200 M)(284 M)(349 M)(356.4 M)(276.9 M)(250.5 M)(236.6 M)(151.6 M)(159.2 M)
INCY(4.9 M)(186.5 M)(44.3 M)(83.1 M)(48.5 M)6.5 M104.2 M(313.1 M)109.5 M446.9 M(295.7 M)948.6 M340.7 M597.6 M627.5 M
DNLI(16.8 M)(16.8 M)(16.8 M)(16.8 M)(16.8 M)(16.8 M)(86.7 M)(88.2 M)(36.2 M)(197.6 M)71.1 M(290.6 M)(326 M)(145.2 M)(152.5 M)
ARGX(4.5 M)(4.5 M)(12.8 M)(8.5 M)(12.5 M)(16.7 M)(22.5 M)(33.7 M)(76.2 M)(182.5 M)(651.2 M)(408.3 M)(709.6 M)(295.1 M)(309.8 M)
HRMY(39.9 M)(39.9 M)(39.9 M)(39.9 M)(39.9 M)(39.9 M)(39.9 M)(39.9 M)(39.9 M)(158.1 M)(51.9 M)34.6 M181.5 M128.9 M135.3 M
ABUS(8.8 M)(9.7 M)29.9 M(14.1 M)(38.8 M)(61.1 M)(384.1 M)(84.4 M)(57.1 M)(153.7 M)(65.2 M)(77.4 M)(69.5 M)(72.8 M)(76.5 M)
IMVT(136.7 M)(136.7 M)(136.7 M)(136.7 M)(136.7 M)(136.7 M)(136.7 M)(136.7 M)(450)(66.4 M)(107.4 M)(156.7 M)(211 M)(259.3 M)(450)
ARQT(5 M)(5 M)(5 M)(5 M)(5 M)(5 M)(5 M)(5 M)(19.3 M)(42 M)(135.7 M)(205.9 M)(321.3 M)(262.1 M)(249 M)
PTGX(11.1 M)(11.1 M)(11.1 M)(11.1 M)(11.1 M)(14.9 M)(37.2 M)(37 M)(38.9 M)(77.2 M)(66.2 M)(122.6 M)(123.4 M)(79 M)(82.9 M)

Maravai Lifesciences and related stocks such as Roivant Sciences, Krystal Biotech, and Prometheus Biosciences Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Maravai Lifesciences financial statement analysis. It represents the amount of money remaining after all of Maravai Lifesciences Holdings operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Maravai Lifesciences Competitive Analysis

The better you understand Maravai Lifesciences competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Maravai Lifesciences' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Maravai Lifesciences' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
MRVI ROIV KRYS RXDX AKRO APLS HALO AGIO INSM RARE
 9.21 
 5.93 
Maravai
 0.17 
 12.11 
Roivant
 0.31 
 185.17 
Krystal
 0.12 
 199.92 
Prometheus
 1.08 
 30.31 
Akero
 1.85 
 34.00 
Apellis
 2.71 
 47.73 
Halozyme
 5.26 
 43.60 
Agios
 3.15 
 74.91 
Insmed
 0.75 
 48.72 
Ultragenyx
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Current Ratio
Net Asset
Profit Margin
EBITDA
Operating Margin
Current Valuation
Price To Book
Retained Earnings
Current Asset
Beta
Number Of Employees
Shares Outstanding
Cash Flow From Operations
Total Debt
Return On Equity
Return On Asset
Number Of Shares Shorted
Book Value Per Share
Current Liabilities
Total Asset
Debt To Equity
Short Ratio
Target Price
Shares Owned By Institutions
Market Capitalization
Price To Earning
Price To Earnings To Growth
Price To Sales
Net Income
Earnings Per Share
Shares Owned By Insiders
Revenue
Working Capital
Cash And Equivalents
Cash Per Share
Gross Profit
Day Typical Price
Accumulation Distribution
Market Facilitation Index
Daily Balance Of Power
Period Momentum Indicator
Rate Of Daily Change
Day Median Price
Price Action Indicator
Relative Strength Index
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

Maravai Lifesciences Competition Performance Charts

Five steps to successful analysis of Maravai Lifesciences Competition

Maravai Lifesciences' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Maravai Lifesciences in relation to its competition. Maravai Lifesciences' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Maravai Lifesciences in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Maravai Lifesciences' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Maravai Lifesciences, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Maravai Lifesciences position

In addition to having Maravai Lifesciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Preferred Stock ETFs Thematic Idea Now

Preferred Stock ETFs
Preferred Stock ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Preferred Stock ETFs theme has 16 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Preferred Stock ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Maravai Lifesciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Maravai Lifesciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Maravai Lifesciences Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Maravai Lifesciences Holdings Stock:
Check out Maravai Lifesciences Correlation with its peers.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Maravai Lifesciences. If investors know Maravai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Maravai Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.33)
Earnings Share
(1.67)
Revenue Per Share
2.044
Quarterly Revenue Growth
(0.03)
Return On Assets
(0.02)
The market value of Maravai Lifesciences is measured differently than its book value, which is the value of Maravai that is recorded on the company's balance sheet. Investors also form their own opinion of Maravai Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Maravai Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Maravai Lifesciences' market value can be influenced by many factors that don't directly affect Maravai Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Maravai Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Maravai Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Maravai Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.